Drug intelligence / Profile preview

Aolanti Weikang

Development stage: Phase 2
Lead developer: Jiangxi Qingfeng Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Aolanti Weikang is a Chinese patent drug developed for the treatment of functional dyspepsia, specifically targeting postprandial discomfort syndrome. It is administered orally in tablet form and has been evaluated in multiple clinical trials, including phase 1b and phase 2c studies, to assess its safety and efficacy in both healthy volunteers and patients with functional dyspepsia. The precise mechanism of action is not specified in available sources. The drug was developed by Jiangxi Qingfeng Pharmaceutical.

Brand names: Aolanti Weikang
Other names: Aolanti Weipang

Beyond the preview

Go deeper on Aolanti Weikang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aolanti Weikang.

Explore the full profile